Print
Email
Print Edition StoriesMonday, March 2, 2009
ImmunoGen due for $6.5M milestone pay
By Mass High Tech staff
Waltham biopharmaceuticals firm ImmunoGen Inc. will receive a $6.5 million milestone payment from Genetech Inc. and Roche Holding AG, stemming from the start of a Phase 3 trial of a treatment for HER2-positive metastatic breast cancer developed by the two companies.
The Phase 3 trial tests T-DM1, which uses ImmunoGen’s DM1 cell-killing agent in combination with Genentech’s anti-HER2 antibody, trastuzumab, as a second-line breast cancer treatment.
The clinical trial consists of 580 patients through about 260 medical centers globally. Some patients will receive the T-DMI treatment alone, while others will receive capecitabine plus lapatinib.
T-DM1 is also about to be reviewed in a Phase 2 clinical trial as a third-line treatment for HER2-positive MBC. This trial is currently enrolling patients and could potentially receive U.S. Food and Drug Administration approval.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
